Biologx
Diepholz
About Biologx
Biologx has undertaken the mission of ensuring accessibility and affordability for life-saving insulin. In their pursuit of making high-quality insulin affordable, BiologX dedicated significant effort to eradicating inefficiencies across the production process. The company has developed distinctive methodologies for manufacturing recombinant human insulin (RHI), facilitating the production of greater insulin volumes within shorter timeframes. This achievement is realized while ensuring affordable pricing for patients globally. BiologX guarantees that their life-saving insulin products will not only meet but also surpass the rigorous USP Reference Standards, signifying the utmost quality within the industry. This endeavor is undertaken with the simultaneous aim of sustaining profits and fostering expansion.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: Seed
- Last round: Seed (Dec 2020)
- Website: biologx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/biologx-2452921 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.